WO2002092032A1 - Use of 3-position cyclosporin derivatives for hair growth - Google Patents
Use of 3-position cyclosporin derivatives for hair growth Download PDFInfo
- Publication number
- WO2002092032A1 WO2002092032A1 PCT/KR2002/000879 KR0200879W WO02092032A1 WO 2002092032 A1 WO2002092032 A1 WO 2002092032A1 KR 0200879 W KR0200879 W KR 0200879W WO 02092032 A1 WO02092032 A1 WO 02092032A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- cyclosporin
- leucine
- hair growth
- growth promoting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Definitions
- the present invention relates to a hair growth promoting agent comprising a cyclosporin derivative as an active ingredient and more particularly, to a hair growth promoting agent comprising cyclosporin derivatives modified in the 3- position as an active ingredient.
- alopecia refers to a phenomenon wherein duration of the anagen growth phase is shortened and the percentage of hairs in the catagen and telogen phases increases, whereby the number of lost hairs is increased excessively and abnormally.
- minoxidil is one of those approved hair-regrowth agents.
- Minoxidil was originally developed as a hypertension drug for the purpose of reducing blood pressure. However, when using this drug, as a side effect, a trichogenous effect was observed and thereafter, this drug became famous as a hair-regrowth agent. Although mechanisms by which minoxidil works as a hair-regrowth agent is not clearly understood, it is inferred that minoxidil increases blood flow by expansion of blood vessels, whereby roots of hairs are supplied with more nutrition and eventually, growth of hairs are promoted.
- minoxidil enhances the expression of vascular endothelial growth factor (VEGF), a growth factor associated with vasodilatation in the dermal papilla which is a main cell making up the hair roots.
- VEGF vascular endothelial growth factor
- minoxidil promotes activation of dermal papilla cells in the roots of hair incubated in vitro, and growth of hair follicles in a tissue culture of follicles in vitro.
- finasteride a main component of Propecia which has started to be sold by Merck, is used for treatment of alopecia. It inhibits conversion of the male hormone testosterone into dihydrotestosterone, which is a more potent male hormone than testosterone.
- the 1 mg finasteride tablet was approved by the US FDA as a hair-regrowth agent for treatment of male pattern hair loss in men only, and is now commercially available. In clinical studies, it has been demonstrated to have a significant trichogenous effect. However, there has been a report that finasteride may inhibit male sexual function as a side effect. Since neither finasteride nor minoxidil show superior effect in clinical tests, and there is concern about side effects, many researches are conducted to develop a new and improved hair-regrowth agents.
- Cyclosporin A a representative cyclosporin, is a cyclic peptide having the following Chemical Formula, which comprises 11 amino acids, including several N-methyl amino acids and D-alanine at No. 8 residue.
- Chemical Formula 1 -MeBmt— Abu— Sar— eLeu— Val— eLeu— Ala— DAIa— eLeu— MeLeu— MeVal- 1 2 3 4 5 6 7 8 9 10 11
- MeBmt is N-me1hyl-(4R)- [(E)-2-butenyl]-4-memyl-I1 ⁇ 1hreonine
- Abu is I_-ot- aminobutyric acid
- Sar is sarco- sine
- MeLeu is N-methyl-L-leucineNal is L-valine
- Ala is L- alanine
- DAIa is D-alanine
- MeVal N-methyl-L-valine.
- the amino acid form of cyclosporin A of the above Chemical Formula 1 is L- configuration, unless otherwise specified.
- the residue numbering of amino acids starts from MeBmt and proceeds clockwise, i.e.
- the derivatives are named by describing the substituent. For example, if sarcosine, being the amino acid residue 3 of cyclosporin A, is substituted with N-methyl-D-Abu 3 or N-methyl-D-Nva 3 , the derivatives thus prepared are named [N-methyl-D-Abu ] cyclosporin A or [N-methyl-D-Nva ] cyclosporin A, respectively.
- N-methyl-L-leucine is abbreviated by MeLeu, N-methyl-L-isoleucine by MeHe, N- methyl-L-Valine by MeVal, N-methyl-L-alanine by MeAla, N-methyl-L-norvaline by MeNva, L-leucine by Leu, L-isoleucine by lie, sarcosine by Sar, L-serine by Ser, L-valine, Val, L-alanine by Ala, D-alanine by DAIa, famine-butyric acid by Abu, L-threonine by Thr, and L-norvaline by Nva.
- the name of the derivative may be cyclosporin 7- thioamide or [ 7 ⁇ 8 CS-NH] cyclosporin, according to different references (Helv. Chim. Acta.74: 1953-1990, 1991; J. Org. Che 58: 673-677, 1993; J. Org. Chem.59: 7249-7258, 1994).
- Pathol., 1997, 150:1433-1441) have been widely conducted, hi comparative experiments on mouse's back, it is shown that cyclosporin has a hair regrowth effect about 100 times superior to minoxidil
- cyclosporin has a hair regrowth effect about 100 times superior to minoxidil
- Japanese Patent Publication Kokai Nos. Sho 60-243008, Sho 62-19512 and Sho 62-19513 disclose use of cyclosporin derivatives as a hair regrowth agent.
- Europe Patent Publication No. 0414632B1 teaches a cyclosporin derivative modified in the 8- position
- PCT Publication No. 93/17039 teaches isocyclosporin.
- United States Patent No. 5,807,820 and British Patent No. 2,218,334A disclose cyclosporins with excellent transdermal absorption, pursuant to the use of cyclosporins as hair restorers.
- the present invention has been made in view of the above problems associated with side effects of cyclosporin A, and it is an object of the present invention to provide a hair growth promoting agent comprising a cyclosporin derivative as an active ingredient, which exerts an excellent hair growth-promotion ability.
- a hair growth promoting agent comprising a 3- position analog of cyclosporin represented by the below Formula 1, as an active ingredient, which is prepared by synthesizing a variety of derivatives thereof and evaluating their hair growth promoting effects, with an aim of developing a novel agent for promoting hair growth.
- A represents N-me l-(4R) -[(E)-2-butmyl]-4-me%l-I ⁇ threonine, (2S,3R,4R,6E)- 3-sulfhydryl-4-me yl-2-(methylamino)-6-octenoic acid or (2S,4R,6E)-3-oxo-4-methyl-2- (methylamino)-6-octenoic acid;
- B represents L-aminoburyric acid (Abu), L-alanine (Ala), L-threonine (Thr), L-valine
- C represents a D-amino acid represented by the general formula 1 ,
- R is one selected from the group consisting of hydrogen, Ci- straight or branched alkyl, alkenyl or alkynyl moieties, substituted or unsubstituted with one or more selected from the group consisting of amino, hydroxy, halo, haloalkyl, ester, alkoxy, cyano, nitro, alkylamino, and -X- R' represented by the general formula 2 below, [General formula 2] -X-R in which,
- X is oxygen or sulfur
- R' is one selected from the group consisting of hydrogen, and -C 6 straight or branched alkyl, alkenyl or alkynyl moieties, substituted or unsubstituted with one or more selected from the group consisting of amino, hydroxy, halo, haloalkyl, ester, alkoxy, cyano, nitro, alleylamino, and dialkylamino;
- D represents N-methyl-L-leucine, ⁇ -hydroxy N-methyl-L-leucine or L-valine
- E represents L-valine or L-norvaline
- F represents N-methyl-L-leucine, ⁇ -hydroxy N-methyl-L-leucine or L-leucine
- G represents L-alanine or L-alanine thioamide ([ 7 ⁇ 8 CS-NH], NH-CHCH 3 -CS-);
- H represents a D-amino acid represented by the general formula 3, [General formula 3] -NH-CH(CH 2 R)-COOH in which, R' is hydrogen or X-R represented by the general formula 4,
- X is oxygen or sulfur
- R is one selected from the group consisting of hydrogen, and Ci-C 6 straight or branched alkyl, alkenyl or alkynyl moieties, substituted or unsubstituted with one or more selected from the group consisting of amino, hydroxy, halo, haloalkyl, ester, alkoxy, cyano, nitro, alkylamino, and dialkylamino;
- I represents N-methyl-L-leucine, ⁇ -hydroxy-N-methyl-L-leucine or L-leucine
- J represents N-methyl-L-leucine, ⁇ -hydroxy-N-methyl-L-leucine or L-leucine
- K represents N-methyl-L-valine or L-valine.
- a hair growth promoting agent comprising a 3-position analog of cyclosporin with an excellent hair growth promoting effect, represented by Formula 2 below, as an active ingredient.
- MeBmt represents N-methyl-(4R)-4-[(E)-2-butenyl]-4-me l-L-1hreonine; L-alanine, L-threonine, L-valine or L-norvaline;
- B' represents N-methyl-D-aminobutyric acid, N-methyl-D-norvaline, D-2- (me ylamino)hexa-4-ynoyl, D-2-(methylamino)pent-4-ynoyl, D-2-meti ylthio-sarcosine, N- methyl-O-propenyl-D-serine or N-methyl-D-serine;
- C represents N-methyl-L-leucine, ⁇ -hydroxy-N-methyl-L-leucine or L-valine
- D' represents L-valine or L-norvaline
- E' represents N-methyl-L-leucine, ⁇ -hydroxy N-methyl-L-leucine or L-leucine
- F represents L-alanine or L-alanine thioamide ([ 7 ⁇ 8 CS-NH], NH-CHCH 3 -CS-)
- G' represents D-alanine or D-serine
- H' represents N-methyl-L-leucine, ⁇ -hydroxy N-methyl-L-leucine or L-leucine
- I' represents N-methyl-L-leucine, ⁇ -hydroxy N-methyl-L-leucine or L-leucine
- MeVal represents N-methyl-L-valine.
- a hair growth promoting agent comprising a 3-position analog of cyclosporin with an excellent hair growth promoting effect, represented by Formula 3 below, as an active ingredient, [Formula 3]
- MeBmt represents N-methyl-(4R)-4-[(E)-2-butmyl]- me
- A" represents L-alanine, L-threonine, L-valine or L-norvaline;
- B" represents N-methyl-D-aminobutyric acid, N-methyl-D-norvaline, D-2-
- a hair growth promoting agent whose composition comprising a 3-position analog of cyclosporin may be formulated in the form of liquid formualtions, sprays, gels, pastes, emulsions, creams, conditioners or shampoos.
- Fig. 1 is a l-NMR spectrum of [N-methyl-D-Abu 3 ] cyclosporin A
- Fig.2 is a 13 C-NMR spectrum of [N-methyl-D-Abu 3 ] cyclosporin A
- Fig.3 is a Ti-NMR spectrum of [N-methyl-D-Nva 3 ] cyclosporin A;
- Fig.4 is a 13 C-NMR spectrum of [N-methyl-D-Nva 3 ] cyclosporin A;
- Fig.5 is a H-NMR spectrum of p-2-(methylamino)hexa-4-ynoyl ] cyclosporin A;
- Fig. 6 is a 13 C-NMR spectrum of P-2-(memylamino)hexa-4-ynoyl 3 ] cyclosporin A;
- Fig.7 is a 1H-NMR spectrum of P-2-(methylamino)pent-4-ynoyl 3 ] cyclosporin A
- Fig. 8 is a 13 C-NMR spectrum of p-2-(methylamino)pent-4-ynoyl 3 ] cyclosporin A;
- Fig.9 is cyclosporin A
- Fig. 10 is a 13 C-NMR spectrum of [D-2-(methylthio)-Sar 3 ] cyclosporin A;
- Fig. 11 is a 1H-NMR spectrum of [N-methyl-O-propenyl-D-Ser 3 ] cyclosporin A;
- Fig. 12 is a 13 C-NMR spectrum of [N-methyl-O-propenyl-D-Ser 3 ] cyclosporin A;
- Fig. 13 is a ⁇ -NMR spectrum of [N-methyl-D-Ser 3 ] cyclosporin A;
- Fig. 14 is a 13 C-NMR spectrum of [N-methyl-D-Ser 3 ] cyclosporin A.
- the present invention will be described in detail, in conjunction with various examples. These examples are provided only for illustrative purposes, and the present invention is not to be construed as being limited to those examples.
- the present inventors chemically synthesized a variety of 3-position analogs of cyclosporin, and hair growth promoting effects thereof were examined.
- the invention provides a hair growth promoting agent comprising a cyclosporin derivative as an active ingredient
- Tetrahydrofiiran (IHF) was added with diisopropyl amine ((i-Pr ⁇ NH) and added with a solution of n-butyl Hthium (BuLi) in hexane under nitrogen atmosphere at -78 °C, followed by stirring for 30 min.
- LDA lithium diisopropylamide
- cyclosporin A in THF was added, stirred for 1 hr, and electrophile was added.
- alkylation was performed employing THF (200 ml), (i-PrhNH (3.2 ml), BuLi (8 ml), cyclosporin A (3.76 g) in 50 ml THF and propargyl bromide (3.57 g). After the temperature of the solution reached room temperature, the solution was further stirred for 24 hrs and added with 40 ml water, followed by concentration. The residue was added with ether (Et 2 O), washed with water and a solution of saturated sodium chloride in sequence, and dried over anhydrous MgSO .
- alkylation was performed employing THF (100 ml), (i-Pr ⁇ NH (1.6 ml), BuLi (4.0 ml), cyclosporin A (1.0 g) in 30 ml THF and methyl disulfide (Me 2 S 2 ) (1.5 ml). The solution was stirred for 14 hrs at 0 °C and added with 20 ml water, followed by concentration. The residue was added with ether (Et 2 O), washed with water and a solution of saturated sodium chloride in sequence, and dried over anhydrous
- composition 1 of Table 1 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Table 1 Formulation of hair tonic (unit: weight %) Ingredients Comp. 1 Comp.2 Comp.3 ethanol 40.0 40.0 40.0
- composition 1 of Table 2 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Table 2 Formulation of hair tonic
- compositions as shown in Table 3 below It was found that the composition 1 of Table 3 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- compositions as shown in Table 4 below It was found that the composition 1 of Table 4 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- composition 1-5 Preparation of hair tonic containing IP-2-methylthio-Sar 3 ] cyclosporin A Individual ingredients were mixed and stirred, and the mixtures were completely dissolved to prepare three hair growth promoting tonics, with compositions as shown in Table 5 below. It was found that the composition 1 of Table 5 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- composition 1 of Table 6 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- compositions as shown in Table 7 below It was found that the composition 1 of Table 7 has a hair growth promoting effect at a level similar to a conventional hair tonic containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Table 7 Formulation of hair tonic
- composition 1 of Table 8 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Table 8 Formulation of hair cream (unit: weight %)
- Ingredients Comp. 1 Comp.2 Comp.3 paraffin 5.0 5.0 5.0 cetostearyl alcohol 5.5 5.5 5.5 petrolatum 5.5 5.5 5.5 glycerin monostearate 3.0 3.0 3.0 polyoxyethyleneoctyldodecylelher 3.0 3.0 3.0 propylparaben 0.3 0.3 0.3 [N-melhyl-D-Abu 3 ] cyclosporin A 0.1 1.0 8.0 glycerin 7.0 7.0 7.0 dipropyleneglycol 20.0 20.0 20.0 polyefhylenegrycol 5.0 5.0 5.0 5.0 5.0 water balance not including flavor and colorant flavor typical typical typical colorant lypical typical typical typical typical typical typical
- composition 1 of Table 9 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Ingredients Comp. 1 Comp.2 Comp.3 paraffin 5.0 5.0 5.0 cetostearyl alcohol 5.5 5.5 5.5 petrolatum 5.5 5.5 5.5 glycerin monostearate 3.0 3.0 3.0 polyoxyethyleneoctyldodecylether 3.0 3.0 3.0 propylparaben 0.3 0.3 0.3
- composition 1 of Table 10 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later
- composition 1 of Table 11 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin as evaluated in an animal experiment according to the Test Example described later.
- Ingredients Comp. 1 Comp.2 Comp.3 paraffin 5.0 5.0 5.0 cetostearyl alcohol 5.5 5.5 5.5 petrolatum 5.5 5.5 5.5 glycerin monostearate 3.0 3.0 3.0 polyoxyethyleneoctyldodecylefher 3.0 3.0 3.0 propylparaben 0.3 0.3 0.3
- compositions as shown in Table 12 below. Water was added to adjust to 100 % the total weight including the oil-phase and water-phase ingredients. It was found that the composition 1 of Table 12 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Table 12 Formulation of hair cream
- Ingredients Comp. 1 Comp.2 Comp.3 paraffin 5.0 5.0 5.0 cetostearyl alcohol 5.5 5.5 5.5 petrolatum 5.5 5.5 5.5 glycerin monostearate 3.0 3.0 3.0 polyoxyethyleneoctyldodecylether 3.0 3.0 3.0 propylparaben 0.3 0.3 0.3
- composition 1 of Table 13 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Ingredients Comp. 1 Comp.2 Comp.3 paraffin 5.0 5.0 5.0 cetostearyl alcohol 5.5 5.5 5.5 petrolatum 5.5 5.5 5.5 glycerin monostearate 3.0 3.0 3.0 polyoxyelhyleneoctyldodecylether 3.0 3.0 3.0 propylparaben 0.3 0.3 0.3
- composition 1 of Table 14 has a hair growth promoting effect at a level similar to a conventional hair cream containing 0.1 % cyclosporin A, as evaluated in an animal experiment according to the Test Example described later.
- Ingredients Comp. 1 Comp.2 Comp.3 paraffin 5.0 5.0 5.0 cetostearyl alcohol 5.5 5.5 5.5 petrolatum 5.5 5.5 5.5 glycerin monostearate 3.0 3.0 3.0 polyoxyethyleneoctyldodecylether 3.0 3.0 3.0 propylparaben 0.3 0.3 0.3 pSf-methy-D-Ser 3 ] cyclosporin A 0.1 1.0 8.0 glycerin 7.0 7.0 7.0 dipropyleneglycol 20.0 20.0 20.0 polyefhyleneglycol 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 water balance not including flavor and colorant flavor typical typical typical colorant typical typical lypical
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 sodium POE laurylsulfuric acid
- Ingredients Comp. 1 Comp.2 Comp.3 cetanol 3.0 3.0 3.0 self-emulsifiable glycerol-monostearate 2.0 2.0 3.0 squalene 10.0 10.0 10.0
- Ingredients Comp. 1 Comp.2 Comp.3 cetanol 3.0 3.0 3.0 self-emulsifiable glycerol-monostearate 2.0 2.0 3.0 squalene 10.0 10.0 10.0 pSF-methyl-D-Nva 3 ] cyclosporin A 1.0 5.0 10.0 propyleneglycol 2.0 2.0 2.0 stearyldimethyl benzylammonium chloride
- Ingredients Comp. 1 Comp.2 Comp.3 cetanol 3.0 3.0 3.0 self-emulsifiable glycerol-monostearate 2.0 2.0 3.0 squalene 10.0 10.0 10.0
- Ingredients Comp. 1 Comp.2 Comp.3 cetanol 3.0 3.0 3.0 self-emulsifiable glycerol-monostearate 2.0 2.0 3.0 squalene 10.0 10.0 10.0 pSf-methyl-O-propenyl-D-Ser 3 ] cyclosporin A 1.0 5.0 10.0 propyleneglycol 2.0 2.0 2.0 stearyldimethyl benzylammonium chloride 8.0 8.0 8.0 (25 wr% aqueous solution) methyl paraoxybenzoic acid 0.2 0.2 0.2 salicylic acid 0.3 0.3 0.3 L-menthol 0.3 0.3 0.3 0.3 water balance balance balance flavor typical typical typical colorant typical typical typical typical typical typical typical
- Ingredients Comp. 1 Comp.2 Comp.3 cetanol 3.0 3.0 3.0 self-emulsifiable glycerol-monostearate 2.0 2.0 3.0 squalene 10.0 10.0 10.0
- cyclosporin derivatives of the invention have a significant hair growth promoting effect, compared to the control in which mice were applied with a vehicle only. Further, the derivatives show a similar level of hair growth promoting effect, with respect to cyclosporin A. Meanwhile, over a course of 30 days, as comparing the appearance of the backs, the mice of the control and all test groups showed no specific skin irritation.
- the cyclosporin derivatives of the invention may be formulated in any form including liquid formulations, sprays, gels, pastes, emulsions, creams, conditioners, shampoos, and the like.
- a variety of forms are available though, considering their high commercial demand, hair tonics, creams, conditioners, and shampoos are provided herein.
- the cyclosporin derivatives exhibit an excellent hair growth promoting effect, compared to the control.
- the present invention provides a hair growth promoting agent comprising a cyclosporin A derivative substituted in the 3-position of cyclosporin A as an active ingredient, which exhibits an excellent hair growth promoting effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0209619A BRPI0209619B8 (en) | 2001-05-11 | 2002-05-11 | hair growth promoting agent |
AU2002258271A AU2002258271B2 (en) | 2001-05-11 | 2002-05-11 | Use of 3-position cyclosporin derivatives for hair growth |
CA2446971A CA2446971C (en) | 2001-05-11 | 2002-05-11 | Use of 3-position cyclosporin derivatives for hair growth |
EP02728237A EP1387660B1 (en) | 2001-05-11 | 2002-05-11 | Use of 3-position cyclosporin derivatives for hair growth |
AT02728237T ATE473730T1 (en) | 2001-05-11 | 2002-05-11 | USE OF 3-POSITION CYCLOSPORINE DERIVATIVES FOR HAIR GROWTH |
MXPA03010027A MXPA03010027A (en) | 2001-05-11 | 2002-05-11 | Use of 3-position cyclosporin derivatives for hair growth. |
JP2002588951A JP4214181B2 (en) | 2001-05-11 | 2002-05-11 | Use of 3-position derivatives of cyclosporine for hair growth |
DE60237003T DE60237003D1 (en) | 2001-05-11 | 2002-05-11 | USE OF 3-POSITION CYCLOSPORIN DERIVATIVES FOR HAIR GROWTH |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0025682A KR100465012B1 (en) | 2001-05-11 | 2001-05-11 | Use of 3-position cyclosporin derivatives for hair growth |
KR2001/25682 | 2001-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002092032A1 true WO2002092032A1 (en) | 2002-11-21 |
Family
ID=19709334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2002/000879 WO2002092032A1 (en) | 2001-05-11 | 2002-05-11 | Use of 3-position cyclosporin derivatives for hair growth |
Country Status (17)
Country | Link |
---|---|
US (2) | US6790830B2 (en) |
EP (1) | EP1387660B1 (en) |
JP (1) | JP4214181B2 (en) |
KR (1) | KR100465012B1 (en) |
CN (1) | CN1248671C (en) |
AT (1) | ATE473730T1 (en) |
AU (1) | AU2002258271B2 (en) |
BR (1) | BRPI0209619B8 (en) |
CA (1) | CA2446971C (en) |
DE (1) | DE60237003D1 (en) |
ES (1) | ES2348225T3 (en) |
MX (1) | MXPA03010027A (en) |
PL (1) | PL208536B1 (en) |
RU (1) | RU2291682C2 (en) |
TR (1) | TR200301931T2 (en) |
WO (1) | WO2002092032A1 (en) |
ZA (1) | ZA200308532B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6987090B2 (en) * | 2002-05-09 | 2006-01-17 | Lg Household & Health Care Ltd. | Use of 3-position cyclosporin derivatives for hair growth |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
WO2010138422A1 (en) * | 2009-05-27 | 2010-12-02 | Allergan, Inc. | Cyclosporin derivatives for enhancing the growth of hair |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020039528A (en) * | 2000-11-22 | 2002-05-27 | 조명재 | Use of cyclosporin 7-thioamide derivatives for hair growth |
KR100865211B1 (en) * | 2001-10-26 | 2008-10-23 | 주식회사 엘지생활건강 | Nonimmunosuppressive [?-hydroxy-n-methyl-l-leucine4]cyclosporin derivatives for protection from antineoplastic chemotherapy-induced hair loss |
WO2007103311A2 (en) * | 2006-03-06 | 2007-09-13 | Rouse Martin D Jr | Thermal vaporizer apparatus |
DE102008060549A1 (en) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Drug-peptide construct for extracellular accumulation |
US8470376B2 (en) | 2009-06-15 | 2013-06-25 | Kao Corporation | NFAT signal inhibitor and calcineurin inhibitor |
BR112013014890B1 (en) | 2010-12-15 | 2023-10-24 | Contravir Pharmaceuticals, Inc | ANALOG COMPOUND OF MOLECULES BELONGING TO THE CYCLOSPORINE FAMILY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC OR PROPHYLACTIC USE OF SAID COMPOUND AND PROCESSES FOR PREPARING THE SAME |
RU2479872C1 (en) * | 2012-01-11 | 2013-04-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Method for correction of ischemic disorders caused by reperfusion liver injury |
EP2705856A1 (en) | 2012-09-07 | 2014-03-12 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. | Compounds for the treatment of neurodegenerative disorders |
KR102469342B1 (en) * | 2021-06-14 | 2022-11-21 | 주식회사 오리엔트바이오 | Controlled-release intralesional injection composition comprising cyclic peptides and method for preparing same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5284826A (en) * | 1989-07-24 | 1994-02-08 | Sandoz Ltd. | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
US5807820A (en) * | 1988-05-13 | 1998-09-15 | Novartis Ag | Cyclosporin compositions for topical application |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60243008A (en) | 1984-05-17 | 1985-12-03 | Wakamoto Pharmaceut Co Ltd | Hair producing and growing tonic |
EP0194972B1 (en) * | 1985-03-11 | 1992-07-29 | Sandoz Ag | Novel cyclosporins |
JPS6219512A (en) | 1985-07-17 | 1987-01-28 | Shiseido Co Ltd | Hair tonic |
JPS6219513A (en) | 1985-07-17 | 1987-01-28 | Shiseido Co Ltd | Hair tonic |
GB8916901D0 (en) * | 1989-07-24 | 1989-09-06 | Sandoz Ltd | Improvements in or relating to organic compounds |
GB9203886D0 (en) * | 1992-02-24 | 1992-04-08 | Sandoz Ltd | Improvements in or relating to organic compounds |
JPH07316023A (en) * | 1994-05-26 | 1995-12-05 | Shiseido Co Ltd | Hair tonic |
BR9609795A (en) * | 1995-07-17 | 1999-03-16 | Chem Ag C | Cyclosporine derivatives having an anti-HIV effect |
FR2757521B1 (en) * | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
HUP0102833A3 (en) * | 1998-06-12 | 2002-03-28 | Chem Ag C | Cyclosporins, process for preparation thereof and their use |
FR2780061B1 (en) * | 1998-06-22 | 2001-09-07 | Rhone Poulenc Rorer Sa | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES |
CA2366312A1 (en) | 1999-03-05 | 2000-09-08 | The University Of Texas Southwestern Medical Center | Method of treating hair loss using non-immunosuppressive compounds |
KR100316604B1 (en) * | 1999-11-19 | 2001-12-12 | 성재갑 | Use of a nonimmunosuppressive cyclosporin A derivative for hair growth |
WO2001035914A1 (en) * | 1999-11-19 | 2001-05-25 | Lg Household & Health Care Ltd | Use of nonimmunosuppressive cyclosporin derivatives for hair growth |
US6521595B1 (en) * | 1999-11-19 | 2003-02-18 | Lg Chemical, Ltd. | Nonimmunosuppressive [γ-hydroxy-methylleucine4] cyclosporin A, hair growth stimulator and external composition for skin using the same |
KR100360716B1 (en) * | 2000-11-22 | 2002-11-13 | 주식회사 엘지생활건강 | Use of cyclosporin A 7-thioamide derivatives for hair growth |
KR20020039528A (en) * | 2000-11-22 | 2002-05-27 | 조명재 | Use of cyclosporin 7-thioamide derivatives for hair growth |
KR100681670B1 (en) * | 2001-02-14 | 2007-02-09 | 주식회사 엘지생활건강 | Use of [ ?-hydroxy-N-methyl-L-leucine9 ] cyclosporin A for hair growth |
KR100695610B1 (en) * | 2001-05-15 | 2007-03-14 | 주식회사 엘지생활건강 | Topical compositions containing nonimmunosuppressive cyclosporin derivatives for treating hair loss |
KR100695611B1 (en) * | 2001-05-17 | 2007-03-14 | 주식회사 엘지생활건강 | The use of Nonimmunosuppressive [?-hydroxy-N-methyl -L-leucine4] cyclosporin derivatives for treating hair loss |
-
2001
- 2001-05-11 KR KR10-2001-0025682A patent/KR100465012B1/en active IP Right Grant
-
2002
- 2002-05-09 US US10/141,723 patent/US6790830B2/en not_active Expired - Lifetime
- 2002-05-11 RU RU2003135846/15A patent/RU2291682C2/en active
- 2002-05-11 CN CNB028096754A patent/CN1248671C/en not_active Expired - Lifetime
- 2002-05-11 PL PL366407A patent/PL208536B1/en unknown
- 2002-05-11 MX MXPA03010027A patent/MXPA03010027A/en active IP Right Grant
- 2002-05-11 DE DE60237003T patent/DE60237003D1/en not_active Expired - Lifetime
- 2002-05-11 TR TR2003/01931T patent/TR200301931T2/en unknown
- 2002-05-11 AT AT02728237T patent/ATE473730T1/en not_active IP Right Cessation
- 2002-05-11 JP JP2002588951A patent/JP4214181B2/en not_active Expired - Lifetime
- 2002-05-11 CA CA2446971A patent/CA2446971C/en not_active Expired - Lifetime
- 2002-05-11 WO PCT/KR2002/000879 patent/WO2002092032A1/en active Application Filing
- 2002-05-11 BR BRPI0209619A patent/BRPI0209619B8/en not_active IP Right Cessation
- 2002-05-11 AU AU2002258271A patent/AU2002258271B2/en not_active Expired
- 2002-05-11 ES ES02728237T patent/ES2348225T3/en not_active Expired - Lifetime
- 2002-05-11 EP EP02728237A patent/EP1387660B1/en not_active Expired - Lifetime
- 2002-11-25 US US10/303,281 patent/US6762164B2/en not_active Expired - Lifetime
-
2003
- 2003-10-31 ZA ZA200308532A patent/ZA200308532B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807820A (en) * | 1988-05-13 | 1998-09-15 | Novartis Ag | Cyclosporin compositions for topical application |
US5284826A (en) * | 1989-07-24 | 1994-02-08 | Sandoz Ltd. | 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins |
Non-Patent Citations (3)
Title |
---|
JACOBS J.P. ET AL: "Use of topical minoxidil therapy for androgenetic alopecia in women", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 32, no. 10, 1993, pages 758 - 762, XP002974595 * |
MAURER M. ET AL: "Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development and relative protection from chemotherapy-induced alopecia", AMERICAN JOURNAL OF PATHOLOGY, vol. 150, no. 4, April 1997 (1997-04-01), PHILADELPHIA, PA, US, pages 1433 - 1442, XP002955318 * |
YAMAMOTO S. ET AL: "Hair growth stimulating effects of cyclosporin A and FK506, potent immunosuppressants", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 7, no. SUPPL., 1994, SHANNON, IR, pages S47 - S52, XP002955301 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6987090B2 (en) * | 2002-05-09 | 2006-01-17 | Lg Household & Health Care Ltd. | Use of 3-position cyclosporin derivatives for hair growth |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
WO2010138422A1 (en) * | 2009-05-27 | 2010-12-02 | Allergan, Inc. | Cyclosporin derivatives for enhancing the growth of hair |
Also Published As
Publication number | Publication date |
---|---|
KR100465012B1 (en) | 2005-01-13 |
CA2446971C (en) | 2011-07-05 |
KR20020086041A (en) | 2002-11-18 |
EP1387660A4 (en) | 2006-05-17 |
MXPA03010027A (en) | 2005-09-08 |
CN1507339A (en) | 2004-06-23 |
ZA200308532B (en) | 2004-07-01 |
DE60237003D1 (en) | 2010-08-26 |
ES2348225T3 (en) | 2010-12-01 |
JP2004530685A (en) | 2004-10-07 |
AU2002258271B2 (en) | 2006-06-29 |
ATE473730T1 (en) | 2010-07-15 |
CA2446971A1 (en) | 2002-11-21 |
CN1248671C (en) | 2006-04-05 |
EP1387660B1 (en) | 2010-07-14 |
US20030207798A1 (en) | 2003-11-06 |
RU2291682C2 (en) | 2007-01-20 |
TR200301931T2 (en) | 2004-09-21 |
US6762164B2 (en) | 2004-07-13 |
JP4214181B2 (en) | 2009-01-28 |
RU2003135846A (en) | 2005-03-27 |
PL366407A1 (en) | 2005-01-24 |
BR0209619A (en) | 2004-03-30 |
PL208536B1 (en) | 2011-05-31 |
BRPI0209619B8 (en) | 2021-05-25 |
BRPI0209619B1 (en) | 2015-05-19 |
US20030186857A1 (en) | 2003-10-02 |
EP1387660A1 (en) | 2004-02-11 |
US6790830B2 (en) | 2004-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6987090B2 (en) | Use of 3-position cyclosporin derivatives for hair growth | |
US6762164B2 (en) | Use of 3-position cyclosporin derivatives for hair growth | |
AU2002258271A1 (en) | Use of 3-position cyclosporin derivatives for hair growth | |
EP1560558B1 (en) | Use of 3-position cyclosporin derivatives for hair growth | |
US20040161399A1 (en) | Use of nonimmunosuppressive [$g(g)-hydroxy-n-methyl-l-leucine4]cyclosporin derivatives for treating hair loss | |
KR100360716B1 (en) | Use of cyclosporin A 7-thioamide derivatives for hair growth | |
US20020165133A1 (en) | Use of [gamma-hydroxy-N-methyl-leucine9] cyclosporin a for hair growth | |
US20040071650A1 (en) | Use of cyclosporin 7-thioamide derivatives for hair growth | |
KR100439467B1 (en) | Use of 3-position cyclosporin derivatives for hair growth | |
KR100605210B1 (en) | Use of 3-position cyclosporin derivatives for hair growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003/08532 Country of ref document: ZA Ref document number: PA/a/2003/010027 Country of ref document: MX Ref document number: 200308532 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002258271 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002728237 Country of ref document: EP Ref document number: 1200300999 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 01843/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2446971 Country of ref document: CA Ref document number: 2002588951 Country of ref document: JP Ref document number: 2003/01931 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028096754 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002728237 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |